Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. With our transformation into a fully integrated oncology company well underway, it’s an exciting time to be part of Team Olema.
Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in Q1 2027 which, if positive, could lead to our first potential approval and commercial launch in 2028. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant could transform the metastatic breast cancer treatment paradigm and provide access to a $15 billion global market opportunity.
Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with the potential to generate further value and meaningfully impact the metastatic breast cancer treatment landscape – particularly in combination with palazestrant. We recently presented encouraging Phase 1 monotherapy data from this program across multiple solid tumor types, are advancing patient enrollment in the ongoing combination arms in MBC, and expect to initiate a Phase 1 study of OP-3136 in combination with Bayer’s darolutamide in metastatic castration-resistant prostate cancer by the end of this year.
Aspiring to transform the metastatic treatment paradigm is an ambitious endeavor that requires a resolute approach to developing better therapies and passionate colleagues dedicated to helping the patients we serve feel better, longer. Team Olema possesses a deep commitment to a shared purpose, the sustained pursuit of excellence, cultivating the courage required to advance our programs, the drive to succeed, and a collective capacity for adaptability through learning, growth, and evolution. We are a small group of nimble self-starters who bring consistency in our quest for the extraordinary every single day.
If you’re ready to be part of a tenacious, courageous, agile, and growing team, join us in making a profound impact, together – for our patients, for your career, and for what’s beyond.
Important Information >>>
We provide equal opportunity to all employees and applicants for employment and believe that great ideas and discoveries come from a mix of expertise, background, and experience. Olema is building a culture where the value of difference is celebrated.
We offer a competitive compensation and benefits package, seeking to provide an open, flexible, and friendly work environment to empower employees and provide them with a platform to develop their long-term careers. A Summary of Benefits is available for all applicants.
Please note: Olema doesn’t accept agency resumes and is not responsible for any fees related to unsolicited resumes. Thank you.
Fraud Alert: We are aware of employment scams where individuals pose as representatives of Olema Oncology and make false use of our company name to defraud job seekers. To protect yourself, please note that Olema’s official email addresses end in @olema.com. Our official corporate website is olema.com; our careers page is olema.com/careers; our LinkedIn page is linkedin.com/company/olema-oncology. Please visit these links for official information from Olema. Communication from any other variant is fraudulent. Olema does not conduct interviews via text message/messaging platforms, will not ask you to download anything as part of your interview, will never request any form of payment, provide upfront payments of any kind, and does not make job offers without an in-person interview.
| Role | Location | Salary | Posted |
|---|---|---|---|
| Associate Director, Global Regulatory Affairs, Compliance and Project ManagementOlema · San Francisco, California | San Francisco, California | $185K – $205K | 2026-11-13 |
| Associate Director, Global Regulatory Affairs, Compliance and Project ManagementOlema · Boston, Massachusetts | Boston, Massachusetts | $185K – $205K | 2026-11-13 |
| Director, Commercial Data ScienceOlema · San Francisco, California | San Francisco, California | — | 2026-11-13 |
| Director, Commercial Data ScienceOlema · Boston, Massachusetts | Boston, Massachusetts | — | 2026-11-13 |
| Director, Commercial Insights and AnalyticsOlema · Boston, Massachusetts | Boston, Massachusetts | $230K – $250K | 2026-11-13 |
| Director, Commercial Insights and AnalyticsOlema · San Francisco, California | San Francisco, California | $230K – $250K | 2026-11-13 |
| Executive Assistant, supporting Chief Financial OfficerOlema · San Francisco, California | San Francisco, California | $120K – $150K | 2026-11-13 |
| Medical Director, Clinical DevelopmentOlema · Boston, Massachusetts | Boston, Massachusetts | $275K – $300K | 2026-11-13 |
| Medical Science Liaison/Senior Medical Science Liaison (Southeast Region)Olema · Remote | Remote | — | 2026-11-13 |
| Senior Director, Commercial Manufacturing and OperationsOlema · Boston, Massachusetts | Boston, Massachusetts | $260K – $285K | 2026-11-13 |
| Senior Director, Commercial Manufacturing and OperationsOlema · San Francisco, California | San Francisco, California | $260K – $285K | 2026-11-13 |
| Senior Director, National and Strategic AccountsOlema · Remote | Remote | $250K – $275K | 2026-11-13 |
| Senior Director, Patient Safety SciencesOlema · San Francisco, California | San Francisco, California | — | 2026-11-13 |
| Senior Director, Patient Safety SciencesOlema · Boston, Massachusetts | Boston, Massachusetts | — | 2026-11-13 |
| Vice President of Information TechnologyOlema · San Francisco, California | San Francisco, California | $335K – $365K | 2026-11-13 |
| Director of Facilities, Laboratory Operations and EHSOlema · San Francisco, California | San Francisco, California | — | 2026-11-11 |